How Multidisciplinary Care and Smarter Tools Can Transform MS Management: Steven Kheloussi, PharmD

Why It Matters

Integrating intelligent tools and multidisciplinary care can close treatment gaps, boost patient outcomes, and reduce overall healthcare costs in the growing MS market.

Key Takeaways

• Decision support tools aggregate patient data for personalized MS therapy.
• Clinician adoption sits around 65%; patient/system use lower.
• Prior authorization hampers timely access to disease‑modifying drugs.
• Multidisciplinary teams boost quality of life and functional outcomes.
• Care coordinators link patients to community resources and reduce friction.

Pulse Analysis

The landscape of multiple sclerosis treatment is shifting from a sole focus on disease‑modifying drugs to a holistic, data‑driven approach. Advanced clinical decision‑support systems pull together disparate data points—relapse frequency, MRI activity, comorbidities, and patient‑reported outcomes—into a single, actionable view within the electronic health record. When designed to complement, not replace, clinician judgment, these tools can surface early disease signals, standardize best‑practice recommendations, and streamline shared decision‑making. However, the promise of automation is tempered by the risk of alert fatigue, underscoring the need for intuitive interfaces that prioritize high‑impact insights.

Beyond technology, the evidence is clear that multidisciplinary care models deliver measurable benefits for people with MS. Pharmacists can monitor adherence, manage side‑effects, and navigate prior‑authorization hurdles, while physical and occupational therapists address mobility and functional decline. Mental‑health specialists mitigate the cognitive and emotional burden, and social workers facilitate employment and accessibility support. Studies consistently show that patients receiving coordinated, team‑based care experience slower disability progression and higher satisfaction scores, translating into reduced hospitalizations and lower long‑term costs for payers.

Implementation remains the biggest obstacle. Adoption rates for decision‑support tools hover near two‑thirds among clinicians, with even lower engagement from patients and health‑system administrators. Prior‑authorization policies, often applied uniformly, further impede timely therapy initiation. Effective solutions involve embedding tools seamlessly into workflow, employing care managers or nurse case‑managers to orchestrate specialist appointments, and leveraging telehealth to reach rural populations. Policymakers and payers that invest in these infrastructure upgrades can unlock the full potential of personalized, multidisciplinary MS care, delivering better outcomes while containing expenditures.